Background
The Response assessment of chemotherapy for gastric carcinoma (the Japanese evaluation criteria) was first introduced in the 11th Japanese edition [1] of the General rules (GR) for gastric cancer study of the Japanese Research Society for Gastric Cancer in 1985.
The principles of the World Health Organization (WHO) criteria were respected in this new method. Two important elements were: (1) using X-ray and endoscopic findings to assess gastric lesions, and (2) a new methodology to evalute diffusely infiltrating tumors.
Primary lesions were classified as: (a) measurable, (b) evaluable but not measurable (lesions extending to more than half the circumference of the lumen of the organ that could not be measured, and lesions with unclear boundaries that were examined carefully and comparatively, not only by an upper gastrointestinal Xray examination but also by endoscopic examination), and (c) diffusely infiltrating lesions, represented by linitis plastica. Findings of regression, defined as a 50% reduction in tumor size in (a) lesions and also an around 50% reduction in the ulcerous area and a flattening of surrounding bank in (b) lesions, were designated as 25% in b-lesions (total response, 16.4%), and 3.2% and 8.3% in c-lesions (total 5.5%), respectively, although median survival time (MST) was the same (180 days) with both regimens. In a total of 169 patients, MST was 282 days in those with a-lesions, 161 days in those with b-lesions, and 189 days in those with c-lesions [5] .
In a pilot chemotherapy study with Doxifluridine (5Ј-DFUR) plus cisplatin (CDDP) in 64 patients, however, response rates were 47.1% in a-lesions, 37% in blesions, and 5% in c-lesions. MST was 273 days in those [10] for primary gastric cancer lesions. Measurable lesion (alesion): more than 50% decrease of total tumor size on X-ray and/or endoscopic examinations for more than 4 weeks. Evaluable but not measurable lesion (b-lesion): findings clearly differ from pretreatment examinations, e.g., showing marked regression and flattening of elevated or ulcerative lesion (estimated decrease of more than 50%) in regard to macroscopic change on X-ray and/or endoscopic examination for more than 4 weeks. Diffusely infiltrating lesion (clesion): enlargement of more than 50% of the gastric lumen of the affected region (striped area) on X-ray examination for more than 4 weeks with a-lesions, 267 days in those with b-lesions, and 287.5 days in those with c-lesions [5] . In 1993, Kurihara et al. [5] reported that, in 8 "minor response (MR)" patients (enlargement of affected area a-lesion b-lesion c-lesion м50%, Ͻ100%) with c-lesions treated with FTM and UFTM, this chemotherapy, study resulted in a prolonged MST of 450.5 days, longer than the 411-day MST in 13 PR patients with a-lesions and the 295.5-day MST in 10 PR patients with b-lesions. Survival times in patients with PR according to the criteria in [1] (enlargement of affected area м100%) were compared with PR those with according to the new criteria (enlargement of affected area м50%) in 55 c-lesion patients (Fig. 3) . MST based on the м50% increase of the affected area in c-lesions was 314 days for PR and 211 days for NC, showing a significant difference, indicating a significant correlation between chemotherapeutic efficacy and survival time in c-lesion patients [5] . Therefore, on the basis of previous study findings, in the 12th edition of the GR [2] , the PR definition for c-lesions was revised. and [2] . In c-lesions, in reference [1] partial response (PR; continuous line) to chemotherapy was defined as 100% enlargement of the affected area for more than 4 weeks, and no change (NC; dotted line) was defined as less than 100% enlargement or nonenlargement for more than 4 weeks, on Xray examination (A). In c-lesions, according to reference [2] PR was defined as more than 50% (but less then 100%) enlargement of the affected area for more than 4 weeks, and NC was defined as less than 50% enlargement or nonenlargement for more than 4 weeks, on X-ray examination (B). According to both references [1] and [2] , progressive disease (PD; dashed line) in c-lesion gastric cancer was defined as a decrease of the affected area on X-ray examination, or the appearance of new lesions Numbers of patients are shown for all variables except for metastatic site (some patients had metastasis at more than one site)
Recently, Koizumi et al. [6] reported 48 responders (53.3%) and 42 nonresponders (46.7%) in a total of 90 patients with inoperable gastric primary tumors treated by various chemotherapies, consisting of fluorinated pyrimidine (i.v. or p.o.) and CDDP, using the Japanese criteria. MSTs were: 9.4 months overall, 12.6 months in responders (14.2 months in 23 a-lesion patients, 11.5 months in 12 b-lesion patients, and 10.5 months in 13 c-lesion patients) and 7.8 months in the nonresponders (11.4 months in 4 a-lesion patients, 7.4 months in 19 b-lesion patients, and 7.2 months in 19 c-lesion patients). It was pointed out that, in inoperable gastric cancer patients without measurable metastatic lesions (for instance, those in liver, lung, and lymph nodes) only 51 of the total of 90 patients could be evaluated by the WHO criteria [7] , which are the most commonly used in the United States and Europe.
Kurihara et al. [8] reported results similar, to those of Koizumi et al. [6] , with 41 responders in a total of 118 patients treated with 5Ј-DFUR plus CDDP, by the Japanese Criteria (response rate, 34.7%); MSTs were: 268 days overall, 425 days in the 41 responders, and 188 days in the 77 nonresponders. However, according to the WHO criteria, and especially in regard to the Response Evaluation Criteria in Solid Tumors RECIST [9] , 35 of the 118 patients above, who had inoperable primary gastric tumors invading adjacent organs, or cancerous peritonitis, not detectable by computed tomography (CT) or magnetic resonance imaging (MRI), could not be enrolled in clinical trials.
Introduction
The first English edition of the Japanese classification of gastric carcinoma was published in 1995 [10] , based on the 12th Japanese edition [2] of The general rules (GR), for gastric cancer study of the Japanese Research Society for Gastric Cancer, with full illustrations and detailed descriptions. To coincide with the establishment of the Japanese Gastric Cancer Association (JGCA) in 1998, the 13th edition of the GR [11] and the 2nd English edition of the JGCA classification, except for "Part IV: response assessment of chemotherapy for gastric carcinoma" [12] , were published after correction and revision of the 12th edition of the GR and the 1st English edition, respectively.
In this article, "Part IV: response assessment of chemo/radiotherapy for gastric carcinoma," which has been translated from the 13th Japanese edition, is introduced. As already described in the 1st English edition in Japan, inoperable gastric tumors, as well as metastatic lesions treated by chemo/radiotherapy, have been assessed. For the assessment of primary gastric lesions, radiological and endoscopic findings are used at 4-week intervals. Primary lesions were classified as follows: (a) measurable, (b) evaluable but not measurable, and (c) diffusely infiltrating lesions (Fig. 1) . Since 1993 (12th edition [2] ), these assessment methods have been widely accepted by specialists after being discussed at our meetings throughout Japan.
On overall evaluations, the treated patients assessed by the Japanese criteria had a higher survival rate (Fig. 2) , suggesting that the antitumor effect was closely related to the survival time [4] . With new regimens, similar results were observed [5, 6] , as described in "Background." Therefore, the response assessments for primary gastric lesions are, in general, the same as those in the 1st English edition. However, as some revisions, considered to be reasonable, were those included, they are summarized below.
Summary of changes

The previous English version of the Japanese classifi-
cation of gastric carcinoma [10] described the assessment of primary gastric lesions, using X-ray and endoscopic findings; the lesions were classified as: (a) measurable lesions, (b) evaluable but not measurable, and (c) diffusely infiltrating. The present version [11] revised the assessment method in detail. 2. Patient status at the start of therapy: (1) Performance status (PS) according to the "WHO criteria," (2) concurrent disease(s) that may influence the outcome of chemotherapy or radiation therapy, (3) description of lesions: presence of previous treatment and recurrence, as well as "the stage" [12] . 3. Therapy description: details of chemotherapy and radiation therapy have to be described. 4. Clinical efficacy, maximum change in pain, anorexia, nausea-vomiting, changes in body weight, PS, serum tumor marker levels, and quality of life (QOL) score on a specified questionnaire [13] [14] [15] . 5. The determination of overall response includes not only eligible cases and complete cases but also the "Full analysis set [16] ," and there have to be population parameters. 6. When evaluating responses in patients with carcinomas, only CR should be included in the calculations. Cytodiagnosis is not necessary in the evaluation of the response; however, when possible, the results should be described separately. 7. Duration of survival, population parameters, and overall response rate should be described. 8. The 1-to 5-year cumulative survival rates in the treated population should be calculated by the Kaplan-Meier method or the life-table method. 9. Adverse drug reactions should describe the toxicity, severity, date of onset, and duration, according to the Revised NCI-Common Toxicity Criteria (CTC) version 2.0, Jan. 30, 1998. 10. Factors related to tumor response should be stratified to evaluate the response.
There are no international guidelines for the assessment of response for primary gastrointestinal lesions. The efficacy assessment is often done only for metastatic lesions. The possibility that primary lesions were not checked despite having a response categorized as PD cannot be ruled out. However, in the RECIST criteria, gastric primary lesions are dealt with as "nontarget lesions" [9] . The Japanese criteria are useful for correlating the antitumor effects achieved by chemotherapies in the primary tumors; however, further studies are warranted, both in Japan and throughout the world.
